Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 26, 2008

View Archived Issues

Studies show surfen to be a heparan sulfate antagonist

Merck & Co reports results from studies with cathepsin K inhibitor odanacatib

Recent patents report novel therapeutic agents for HCV infection

New anticancer agents described in recent patents

Kaken launches new formulation Adofeed Pap 80 mg in Japan

Novel agents for respiratory and allergic disorders disclosed in recent patent literature

New antiviral drug company formed, Cocrystal Discovery

Omrix enrolls initial 90 patients for interim analysis in Fibrin Pad phase II trial

Paion presents update on phase I CNS-7056 study

SciClone presents promising phase II results for SCV-07 in hepatitis C

Clinical data for rheumatoid arthritis drug candidate VEL-0230 presented

Akesis expands preclinical safety program for AKP-020

Novel TNF-alpha antagonists developed at Ensemble Discovery

Athersys provides update on ATHX-105 development and results of recent studies

Preliminary results for AMG-386 in combination with other antiangiogenic agents in solid tumors

Belinostat in combination with carboplatin and paclitaxel evaluated in phase I/II cancer studies

Cornerstone initiates CPI-613 trial for the treatment of cancer

Metabasis initiates MB-07803 trial in patients with type 2 diabetes

Oramed commences phase IIa oral insulin trials in patients with type 1 diabetes

PolyMedix starts dosing in phase I novel anticoagulant antagonist trial

Baxter initiates phase III Gammagard Liquid trial for the treatment of AD

MAA for lacosamide in diabetic neuropathic pain withdrawn; product launched in E.U. for seizures

CHMP issues positive opinion for Kuvan for hyperphenylalaninemia

Abstral receives U.K. marketing authorization for breakthrough cancer pain

Aveo initiates first SCH-900105 trial in patients with solid tumors and lymphomas

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld Science
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...